Nephrology Prior Authorization and Denial Guide
Prior authorization requirements and denial patterns for nephrology, including ESRD monthly capitation billing (CPT 90951–90962), renal biopsy documentation requirements, erythropoiesis-stimulating agent (ESA) coverage criteria for pre-dialysis CKD, and SGLT2 inhibitor prior authorization for CKD. Grounded in Aetna Medical Policy for ESAs and renal disease treatment, UHC CDG Nephrology, CMS ESRD billing rules, and KDIGO clinical practice guidelines.
ESRD monthly management: nephrologists billing CPT 90951–90962 must document that the physician personally performed or directly supervised the dialysis visit on the required number of occasions during the month (at least one face-to-face visit per month for outpatient dialysis). The code selection depends on the number of physician face-to-face visits per month. Home dialysis patients billed under 90963–90966 require documentation that the physician reviews the results of home dialysis and provides monthly oversight. CO-4 denials for incorrect code selection based on visit count are common.
ESA therapy for pre-dialysis CKD: epoetin alfa (J0885) and darbepoetin alfa (J0882) require prior authorization for non-dialysis CKD patients. Coverage criteria require Hgb below 10 g/dL on two measurements 30 days apart, documented CKD with GFR below 60, and evaluation and treatment of reversible causes of anemia (iron deficiency, B12/folate deficiency, hypothyroidism). Medicare ESRD bundle rates include ESAs for dialysis patients — separate billing is not permitted. Renal biopsy requires documentation of the clinical indication — unexplained hematuria with proteinuria, nephrotic syndrome, or unexplained acute kidney injury — and imaging confirming accessible kidney anatomy.